目的对所获的PS1/APP双转基因阿尔茨海默病(A lzhe im er d isease,AD)模型小鼠进行基因鉴定,进一步对其进行组织学分析,检测老年斑(sen ile p laque,SP)的形成情况。方法设计特定的引物,PCR扩增转入基因组DNA中的APP基因,对转入PS1/APP的小鼠应用刚果红染色结合免疫组化观察Aβ沉积、小胶质细胞和星型胶质细胞的活化。结果与未转入的阴性对照相比,在PS1/APP双转基因的AD小鼠皮质和海马内可见Aβ斑块形成,围绕在Aβ斑块周围的小胶质细胞和星形胶质细胞处于活化状态,形成典型的SP结构。结论我们获得的PS1/APP双转基因小鼠能够模拟AD患者脑内的主要病理过程,提供有效的实验动物模型。
目的:使用Meta分析的方法比较单纯抗凝治疗与血管内治疗颅内静脉窦血栓形成(CVST)的安全性与有效性。方法:检索PubMed、Embase、知网、维普、万方数据库,检索时限从2000年1月1日开始至2023年12月31日。应用RevManV 5.4软件对纳入的文献进行Meta分析。结果:共有7篇符合要求的文献纳入分析,总计CVST患者489人,其中血管内治疗组240人,单纯抗凝治疗组249人。Meta分析结果显示,血管内治疗组治疗后mRS评分低于单纯抗凝治疗(MD = −0.38, 95% CI: −0.46~−0.30, P 2 = 60%, P = 0.02)。治疗后血管再通率血管内治疗组优于单纯抗凝治疗组(OR = 6.55, 95% CI: 2.70~15.90, P Objective: To compare the safety and efficacy of intravascular treatment versus anticoagulation alone for cerebral venous sinus thrombosis (CVST) using a Meta-analysis approach. Methods: Digital libraries, including PubMed, Embase, CNKI, Wanfang, and VIP, were searched for relevant studies published from January 1, 2000, to December 31, 2023. The included studies were assessed using RevManV 5.4 software for data extraction and quality evaluation. Results: A total of seven eligible studies involving 489 CVST patients (240 in the intravascular treatment group and 249 in the anticoagulation group) were included in the analysis. The Meta-analysis results showed that post-treatment modified Rankin Scale (mRS) scores were significantly lower in the intravascular treatment group compared to the anticoagulation group (MD = −0.38, 95% CI: −0.46~−0.30, P 2 = 60%, P = 0.02). The rate of vascular re-establishment after treatment was significantly higher in the intravascular treatment group (OR = 6.55, 95% CI: 2.70~15.90, P < 0.05). However, there were no statistically significant differences between the groups in terms of post-treatment mortality (OR = 0.86, 95% CI: 0.25~2.96, P = 0.81) or the incidence of bleeding events (OR = 0.34, 95% CI: 0.10~1.16, P = 0.09). Conclusions: Compared to anticoagulation alone, intravascular treatm
